This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources.(August 2020) (Learn how and when to remove this template message)
Amgen Inc.
Headquarters in Thousand Oaks, California
Formerly
Applied Molecular Genetics (1980–1983)
Company type
Public
Traded as
Nasdaq: AMGN
Nasdaq-100 component
DJIA component
S&P 100 component
S&P 500 component
ISIN
US0311621009
Industry
Biotechnology
Founded
April 8, 1980; 44 years ago (1980-04-08)
Headquarters
Thousand Oaks, California, U.S.
Key people
Robert A. Bradway (chairman, president & CEO)
Products
Aimovig
Aranesp
Blincyto
Epogen
Kineret
Enbrel
Kyprolis
Neulasta
Neupogen
Nplate
Parsabiv
Prolia
Repatha
Sensipar/Mimpara
Vectibix
Xgeva
Revenue
US$28.19 billion (2023)
Operating income
US$7.897 billion (2023)
Net income
US$6.717 billion (2023)
Total assets
US$97.15 billion (2023)
Total equity
US$6.232 billion (2023)
Number of employees
c. 26,700 (2023)
Website
amgen.com
Footnotes / references [1][2]
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.[3][4] One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000[5] (8.5% of total city employment)[6] and included hundreds of scientists, making Amgen the largest employer in Ventura County.[7][8] As of 2022, Amgen has approximately 24,000 staff in total.[9]
In 2019, the company's largest selling products were Enbrel (etanercept),[10] a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy.[11] Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).
^"About Amgen Fact Sheet". amgen.com. Retrieved 9 March 2020.
^"US SEC: 2023 Form 10-K Amgen Inc". U.S. Securities and Exchange Commission. February 14, 2024.
^Amgen History official site page accessed January 2, 2016
^Ronald Vogel. Pharmaceutical Economics and Public Policy. CRC Press, 2007. ISBN 9781439801345. P. 208
^Biasotti, Tony (9 April 2022). "In Thousand Oaks, biotech execs discuss industry's 'rising tide,' lament area's lack of housing". Pacific Coast Business Times. Retrieved 19 September 2022.
^"Annual Comprehensive Financial Report". City of Thousand Oaks, California. 30 June 2021. p. 156. Retrieved 19 September 2022.
^Cite error: The named reference Baker, Pam 2002 Page 37 was invoked but never defined (see the help page).
^"Biotech giant Amgen has big plans for new plant". Moorpark Acorn. 16 February 2018.
^Talhelm, Matt (7 March 2022). "Amgen to offer workers an average salary of $119,510 at new facility". WRAL TechWire. Retrieved 20 September 2022.
^Blankenship, Kyle (27 July 2020). "The top 20 drugs by global sales in 2019". Fierce Pharma. Retrieved 12 July 2022.
^Hagen, Tony (4 February 2021). "Amgen Profits Get a Ride on Biosimilar Growth". The Center For Biosimilars. Retrieved 12 July 2022.
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California...
The Tour of California (officially sponsored as the Amgen Tour of California) was an annual professional road cycling stage race on the UCI World Tour...
The Centre for Alternative Technology (CAT) (Welsh: Canolfan y Dechnoleg Amgen) is an eco-centre in Montgomeryshire, Powys, Wales dedicated to demonstrating...
underreporting in the FOURIER study have attracted some controversy in the media. Amgen submitted a biologics license application (BLA) for evolocumab to the FDA...
the UK in 2015. In 2019, Amgen acquired Otezla from Celgene for $13.4 billion. In 2020, Otezla generated $2.2 billion for Amgen. Apremilast was approved...
trial. Obicetrapib was initially developed by Amgen as AMG-899 and was abandoned in 2017. In 2020, Amgen licensed the drug to NewAmsterdam Pharma. Ballantyne...
a hormone that regulates platelet production. The drug was developed by Amgen through a restricted usage program called NEXUS. During development and...
The 2015 Amgen Tour of California was the tenth edition of the Tour of California cycling stage race. It was held from May 10–17, and rated as a 2.HC...
The 2008 Tour of California was the third edition of an eight-day, 650-mile (1,045 km) stage race, which began in Palo Alto (Stanford University), then...
entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA...
eventually sold the license to News Corp. In 2006, Salzman co-founded the AMGEN Tour of California. The Tour of California is the only event on the top-level...
cells that break down bone. It was developed by the biotechnology company Amgen. Denosumab is used for those with osteoporosis at high risk for fractures...
ExxonMobil. Salesforce's ascension to the Dow Jones was concurrent with that of Amgen and Honeywell. Because the Dow Jones factors its components by market price...
needed] and the Amgen Bioprocessing Center. The Amgen Bioprocessing Center was funded by a 2004 grant of $2 million to KGI from Amgen, a pharmaceutical...
right treatment pathway for breast cancer patients. Owkin collaborated with Amgen to test the ability of AI to improve cardiovascular prediction. In November...
Full caption: Amgen Inc., et al. v. Steve Harris, et al. Citations: 577 U.S. ___ Prior history: Dismissed, No. 07-05442, C.D. Cal.; rev'd, 738 F. 3d 1026...
previous subsidiaries Carrier Global or Otis Worldwide. On August 31, 2020, Amgen, Honeywell, and Salesforce.com replaced ExxonMobil, Pfizer, and Raytheon...
Qualcomm Board of Directors Name Background Robert A. Bradway Chair and CEO, Amgen Dave Calhoun President and CEO, The Boeing Company Lynne M. Doughttie Former...
than 300 publications during his career. Amgen: In May 1999, Genmab entered a sub-license agreement with Amgen where it would gain rights to the IL15 antibodies...
EmPOWERED Health Program: Launched in November 2019 with funding from Amgen, the program works to empower cancer patients to become actively involved...
Austronesian language spoken by about 2000 individuals between the Avio and Amgen rivers in West New Britain Province, Papua New Guinea on the island of New...
Global Information
US$28.19 billion (2023)
US$7.897 billion (2023)